Plasma cell leukemia

Common Name(s)

Plasma cell leukemia

Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Plasma cell leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Plasma cell leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Plasma cell leukemia" returned 116 free, full-text research articles on human participants. First 3 results:

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
 

Author(s): Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, Maria Kotsopoulou, Eurydiki Michalis, Chrysanthi Vadikolia, Marie-Christine Kyrtsonis, Argiris Symeonidis, Nikolaos Giannakoulas, Chrissa Vadikolia, Michalis Michael, Christina Kalpadakis, Theodora Gougopoulou, Chrystalla Prokopiou, Georgia Kaiafa, Dimitrios Christoulas, Maria Gavriatopoulou, Evlampia Giannopoulou, Vasiliki Labropoulou, Evgenia Verrou, Efstathios Kastritis, Pavlina Konstantinidou, Achilles Anagnostopoulos, Meletios A Dimopoulos

Journal:

 

We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based combinations; 40% underwent autologous stem cell transplantation ...

Last Updated: 31 Dec 1969

Go To URL
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
 

Author(s): Beenu Thakral, Sa A Wang

Journal: Blood. 2017 09;130(13):1600.

 

Last Updated: 31 Dec 1969

Go To URL
Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
 

Author(s): Beenu Thakral, Tariq Muzzafar

Journal: Blood. 2017 07;130(2):231.

 

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Plasma cell leukemia" returned 13 free, full-text review articles on human participants. First 3 results:

Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature.
 

Author(s): Prithal Gangadhar, Zulfikar Ahmed, Muktha R Pai, I Sandhya

Journal: Indian J Pathol Microbiol. ;59(4):541-544.

 

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma accounting for 2-3% of all plasma cell dyscrasias characterized by the presence of circulating plasma cells. The diagnosis is based on the % (≥20%) and absolute number (≥2x10 9 /L) of plasma cells in the peripheral ...

Last Updated: 31 Dec 1969

Go To URL
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
 

Author(s): Vittorio Simeon, Katia Todoerti, Francesco La Rocca, Antonella Caivano, Stefania Trino, Marta Lionetti, Luca Agnelli, Luciana De Luca, Ilaria Laurenzana, Antonino Neri, Pellegrino Musto

Journal:

 

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. ...

Last Updated: 31 Dec 1969

Go To URL
[Plasma cell leukemia: three case-reports and review of literature].
 

Author(s): Hicham Eddou, El Mehdi Mahtat, Hamid Zahid, Hicham El Maaroufi, Selim Jennane, Nezha Messaoudi, Kamal Doghmi, Mohamed Mikdame

Journal: Ann. Biol. Clin. (Paris). ;71(6):698-702.

 

Plasma cell leukemia (LP) is a rare hematologic malignancy. Its prognosis is very derogatory. It is defined by the presence in circulating blood of more than 2 G/L plasmocytes or greater than 20% of the total leukocytes. It comes in two forms: secondary plasma cell leukemia complicating ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
 

Status: Recruiting

Condition Summary: Plasma Cell Leukemia; Plasma Cell Myeloma; Plasmacytoma

 

Last Updated: 13 Aug 2018

Go to URL
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
 

Status: Recruiting

Condition Summary: Plasma Cell Leukemia; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma

 

Last Updated: 16 Apr 2018

Go to URL